DLBCL, NOS GENETIC SUBTYPES
Clinical trials for DLBCL, NOS GENETIC SUBTYPES explained in plain language.
Never miss a new study
Get alerted when new DLBCL, NOS GENETIC SUBTYPES trials appear
Sign up with your email to follow new studies for DLBCL, NOS GENETIC SUBTYPES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo attack on tough lymphoma shows promise
Disease control OngoingThis study tests whether combining the drug acalabrutinib with a cell therapy called liso-cel can shrink or eliminate aggressive B-cell lymphomas that have returned or not responded to prior treatments. About 28 adults with these hard-to-treat cancers will receive the combination…
Matched conditions: DLBCL, NOS GENETIC SUBTYPES
Phase: PHASE2 • Sponsor: Patrick C. Johnson, MD • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
New CAR T-Cell therapy shows promise for tough lymphoma cases
Disease control OngoingThis study tests a new type of CAR T-cell therapy for adults with large B-cell lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to better target and kill cancer cells. The main goals are to find the safest dose and…
Matched conditions: DLBCL, NOS GENETIC SUBTYPES
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC